These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 35923849)

  • 1. Potential mesenchymal stem cell therapeutics for treating primary biliary cholangitis: advances, challenges, and perspectives.
    Yang Y; Zhao RC; Zhang F
    Front Cell Dev Biol; 2022; 10():933565. PubMed ID: 35923849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesenchymal Stem Cells as New Therapeutic Agents for the Treatment of Primary Biliary Cholangitis.
    Arsenijevic A; Harrell CR; Fellabaum C; Volarevic V
    Anal Cell Pathol (Amst); 2017; 2017():7492836. PubMed ID: 29410945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update.
    Bowlus CL; Kenney JT; Rice G; Navarro R
    J Manag Care Spec Pharm; 2016 Oct; 22(10-a-s Suppl):S3-S15. PubMed ID: 27700211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New developments in the treatment of primary biliary cholangitis - role of obeticholic acid.
    Jhaveri MA; Kowdley KV
    Ther Clin Risk Manag; 2017; 13():1053-1060. PubMed ID: 28860789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesenchymal stem cell-based treatment in autoimmune liver diseases: underlying roles, advantages and challenges.
    He C; Yang Y; Zheng K; Chen Y; Liu S; Li Y; Han Q; Zhao RC; Wang L; Zhang F
    Ther Adv Chronic Dis; 2021; 12():2040622321993442. PubMed ID: 33633826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Advances in the treatment of primary biliary cholangitis].
    Li YM; Wang QX; Ma X
    Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):805-809. PubMed ID: 29325272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The challenges of primary biliary cholangitis: What is new and what needs to be done.
    Terziroli Beretta-Piccoli B; Mieli-Vergani G; Vergani D; Vierling JM; Adams D; Alpini G; Banales JM; Beuers U; Björnsson E; Bowlus C; Carbone M; Chazouillères O; Dalekos G; De Gottardi A; Harada K; Hirschfield G; Invernizzi P; Jones D; Krawitt E; Lanzavecchia A; Lian ZX; Ma X; Manns M; Mavilio D; Quigley EM; Sallusto F; Shimoda S; Strazzabosco M; Swain M; Tanaka A; Trauner M; Tsuneyama K; Zigmond E; Gershwin ME
    J Autoimmun; 2019 Dec; 105():102328. PubMed ID: 31548157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists.
    Abenavoli L; Procopio AC; Fagoonee S; Pellicano R; Carbone M; Luzza F; Invernizzi P
    Diseases; 2020 Jun; 8(2):. PubMed ID: 32532037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigational drugs in phase II clinical trials for primary biliary cholangitis.
    Silveira MG; Lindor KD
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1115-1121. PubMed ID: 28836457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis.
    Sarcognato S; Sacchi D; Grillo F; Cazzagon N; Fabris L; Cadamuro M; Cataldo I; Covelli C; Mangia A; Guido M
    Pathologica; 2021 Jun; 113(3):170-184. PubMed ID: 34294935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesenchymal stem cells alleviate experimental autoimmune cholangitis through immunosuppression and cytoprotective function mediated by galectin-9.
    Fan J; Tang X; Wang Q; Zhang Z; Wu S; Li W; Liu S; Yao G; Chen H; Sun L
    Stem Cell Res Ther; 2018 Sep; 9(1):237. PubMed ID: 30223894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pathogenesis, models and therapeutic advances of primary biliary cholangitis.
    Li H; Guan Y; Han C; Zhang Y; Liu Q; Wei W; Ma Y
    Biomed Pharmacother; 2021 Aug; 140():111754. PubMed ID: 34044277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics.
    Patel A; Seetharam A
    J Clin Exp Hepatol; 2016 Dec; 6(4):311-318. PubMed ID: 28003721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Management of Primary Biliary Cholangitis-Strategies and Evolving Trends.
    Gao L; Wang L; Woo E; He X; Yang G; Bowlus C; Leung PSC; Gershwin ME
    Clin Rev Allergy Immunol; 2020 Oct; 59(2):175-194. PubMed ID: 31713023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholestatic liver diseases: new targets, new therapies.
    Santiago P; Scheinberg AR; Levy C
    Therap Adv Gastroenterol; 2018; 11():1756284818787400. PubMed ID: 30159035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic cholestatic diseases.
    Poupon R; Chazouillères O; Poupon RE
    J Hepatol; 2000; 32(1 Suppl):129-40. PubMed ID: 10728800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in the diagnosis and treatment of primary biliary cholangitis.
    Huang YQ
    World J Hepatol; 2016 Nov; 8(33):1419-1441. PubMed ID: 27957241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and management of primary biliary cirrhosis.
    Ali AH; Carey EJ; Lindor KD
    Expert Rev Clin Immunol; 2014 Dec; 10(12):1667-78. PubMed ID: 25382237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S100 calcium binding protein A6 and associated long noncoding ribonucleic acids as biomarkers in the diagnosis and staging of primary biliary cholangitis.
    Dong XH; Dai D; Yang ZD; Yu XO; Li H; Kang H
    World J Gastroenterol; 2021 May; 27(17):1973-1992. PubMed ID: 34007134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.